ES2191032T3 - Oncoproteina protein-quinasa. - Google Patents

Oncoproteina protein-quinasa.

Info

Publication number
ES2191032T3
ES2191032T3 ES94922622T ES94922622T ES2191032T3 ES 2191032 T3 ES2191032 T3 ES 2191032T3 ES 94922622 T ES94922622 T ES 94922622T ES 94922622 T ES94922622 T ES 94922622T ES 2191032 T3 ES2191032 T3 ES 2191032T3
Authority
ES
Spain
Prior art keywords
jnk
kinase
jun
activation domain
terminal activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94922622T
Other languages
English (en)
Inventor
Michael Karin
Masahiko Hibi
Anning Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26788998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2191032(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/094,533 external-priority patent/US5534426A/en
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of ES2191032T3 publication Critical patent/ES2191032T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)

Abstract

SE PRESENTA UN POLIPEPTIDO AISLADO (JNK) QUE SE CARACTERIZA PORQUE TIENE UN PESO MOLECULAR DE 46KD SEGUN QUEDA DETERMINADO UTILIZANDO UN GEL REDUCIDO SDS-PAGE, QUE TIENE LA ACTIVIDAD SERINA TREONINA QUINASA, FOSFORILANDO EL DOMINIO DE ACTIVACION N-TERMINAL DE C-JUN Y SECUENCIAS DE POLINUCLEOTIDOS Y UN METODO PARA LA DETECCION DEL JNK. JNK FOSFORILA EL DOMINIO DE ACTIVACION N-TERMINAL DE C-JUN QUE AFECTA A LA EXPRESION DE GENES DE LAS REGIONES AP-1.
ES94922622T 1993-07-19 1994-07-18 Oncoproteina protein-quinasa. Expired - Lifetime ES2191032T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/094,533 US5534426A (en) 1993-07-19 1993-07-19 Oncoprotein protein kinase
US08/220,602 US6514745B1 (en) 1993-07-19 1994-03-25 Oncoprotein protein kinase

Publications (1)

Publication Number Publication Date
ES2191032T3 true ES2191032T3 (es) 2003-09-01

Family

ID=26788998

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94922622T Expired - Lifetime ES2191032T3 (es) 1993-07-19 1994-07-18 Oncoproteina protein-quinasa.

Country Status (11)

Country Link
US (7) US6514745B1 (es)
EP (2) EP0728143B1 (es)
JP (3) JP2986548B2 (es)
AT (1) ATE233785T1 (es)
AU (2) AU685484B2 (es)
CA (2) CA2166981C (es)
DE (1) DE69432223T2 (es)
DK (1) DK0728143T3 (es)
ES (1) ES2191032T3 (es)
PT (1) PT728143E (es)
WO (2) WO1995003324A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985558A (en) 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
US6001584A (en) 1993-07-19 1999-12-14 The Regents Of The University Of California Oncoprotein protein kinase
US6846644B2 (en) * 1993-07-19 2005-01-25 The Regents Of The University Of California Oncoprotein protein kinase
US5925557A (en) * 1994-09-29 1999-07-20 The Regents Of The University Of California DNA encoding mitogen activated protein kinase, FRK
US6132978A (en) * 1995-12-19 2000-10-17 National Jewish Medical And Research Center Method to regulate CD40 signaling
WO1998006836A2 (en) * 1996-08-16 1998-02-19 Genencor International, Inc. Expression system derived from the lipase regulation cascade of pseudomonas alcaligenes
US5989885A (en) * 1997-01-10 1999-11-23 Myriad Genetics, Inc. Specific mutations of map kinase 4 (MKK4) in human tumor cell lines identify it as a tumor suppressor in various types of cancer
JP2001518881A (ja) 1997-03-28 2001-10-16 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 乳癌治療剤としての有糸分裂活性化プロテインキナーゼのアンチセンスオリゴヌクレオチド
US6007991A (en) * 1997-03-28 1999-12-28 The Research Foundation Of Suny Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6809193B2 (en) * 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US20070149472A1 (en) * 1997-08-13 2007-06-28 Mckay Robert Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
EP1820854B1 (en) * 1997-10-03 2010-07-28 University of Massachusetts JNK3 modulators and methods of use
US6943000B2 (en) * 1997-10-03 2005-09-13 University Of Massachusetts JNK3 modulators and methods of use
DE69933856D1 (de) * 1998-02-13 2006-12-14 Koester Hubert Verwendung von ribozymen zur bestimmung der funktion von genen
US6897019B1 (en) * 1998-04-17 2005-05-24 Tufts College Methods for treating and preventing insulin resistance and related disorders
US6207458B1 (en) 1998-05-07 2001-03-27 University Of Washigton/Stowers Insitute For Medical Research Proteins capable of regulating NF-κB JNK and apoptosis pathways and methods of using the same
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
EP0984070A1 (en) * 1998-08-31 2000-03-08 Boehringer Ingelheim International GmbH Method for identifying substances for the treatment of disorders associated with c-Jun-mediated apoptosis
ATE556713T1 (de) * 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
FR2788531B1 (fr) * 1999-01-20 2003-01-31 Aventis Pharma Sa Nouveaux polypeptides derives de la proteine jnk3 humaine, leurs variants, les sequences nucleotidiques correspondantes, et leurs utilisations
EP1144651A1 (fr) 1999-01-20 2001-10-17 Aventis Pharma S.A. Polypeptides derives de jnk3
ATE385503T1 (de) 1999-06-28 2008-02-15 Inter K Pty Ltd Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US7232897B2 (en) * 2001-04-24 2007-06-19 Harvard University, President And Fellows Of Harvard College Compositions and methods for modulating NH2-terminal Jun Kinase activity
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
JP2004537291A (ja) * 2001-05-24 2004-12-16 セフアロン・インコーポレーテツド 新規混合系統キナーゼ（７）（ｍｌｋ７）ポリペプチド、それをコードするポリヌクレオチド、およびそれらの使用方法
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
AU2003209116A1 (en) * 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
AUPS078002A0 (en) * 2002-02-27 2002-03-21 Unisearch Limited Dnazyme therapeutics
AU2003294668A1 (en) * 2002-09-06 2004-04-08 Institut Curie Use of inhibitors of compounds involved in the jun kinase (jnk) biochemical cellular pathway for the treatment or diagnosis of liposarcomas
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
PT1636585E (pt) * 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
US20050020391A1 (en) * 2003-07-17 2005-01-27 Pinnacle Sports Equipment Co., Inc. Bamboo bat and method of manufacture
JP4777887B2 (ja) 2003-07-23 2011-09-21 バイエル、ファーマシューテイカルズ、コーポレイション 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素
GB2409679B (en) 2003-10-17 2005-12-28 Inter K Pty Ltd Anti-cancer agents which inhibit the interaction between integrins and MAP kinases.
US20080039377A1 (en) * 2004-04-08 2008-02-14 Applied Research Systems Ars Holding N.V. Composition Comprising a Jnk Inhibitor and Cyclosporin
AU2007356036A1 (en) * 2007-06-29 2009-01-08 Newsouth Innovations Pty Limited Treatment of rheumatoid arthritis
US20110105408A1 (en) * 2008-02-22 2011-05-05 Inter-K Pty Limited Therapeutic peptides
EP4000596A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2109481A1 (en) * 1992-10-29 1994-04-30 Lea Eisenbach Anti-metastatic vaccine

Also Published As

Publication number Publication date
JPH09500535A (ja) 1997-01-21
DE69432223D1 (de) 2003-04-10
US5994513A (en) 1999-11-30
EP0728143A4 (en) 1999-04-21
JP2000023681A (ja) 2000-01-25
PT728143E (pt) 2003-06-30
WO1995003324A1 (en) 1995-02-02
EP0728143B1 (en) 2003-03-05
AU700137B2 (en) 1998-12-24
JP3745558B2 (ja) 2006-02-15
JPH09507384A (ja) 1997-07-29
AU7366894A (en) 1995-02-20
DE69432223T2 (de) 2003-08-21
EP0728143A1 (en) 1996-08-28
AU7338094A (en) 1995-02-20
US5837244A (en) 1998-11-17
ATE233785T1 (de) 2003-03-15
US5804399A (en) 1998-09-08
US6514745B1 (en) 2003-02-04
CA2166981C (en) 2000-11-07
JP2925740B2 (ja) 1999-07-28
AU685484B2 (en) 1998-01-22
US5593884A (en) 1997-01-14
WO1995003323A1 (en) 1995-02-02
JP2986548B2 (ja) 1999-12-06
US5605808A (en) 1997-02-25
EP0726908A4 (en) 1999-04-07
EP0726908A1 (en) 1996-08-21
DK0728143T3 (da) 2003-07-07
US6193965B1 (en) 2001-02-27
CA2167302A1 (en) 1995-02-02

Similar Documents

Publication Publication Date Title
ES2191032T3 (es) Oncoproteina protein-quinasa.
DK0698105T3 (da) Nukleotidsekvenser til styring af ekspressionen af DNAsekvenser i en værtscelle
HUT77431A (hu) Fonálféregből kivont szerinproteáz-inhibitorok és véralvadásgátló proteinek
ATE490311T1 (de) Mutanten der alpha-amylase
ATE273718T1 (de) Methoxyethoxy-oligonukleotide zur regulierung der proteinkinase c expression
DE69825066D1 (de) Veränderte proteinkinasen, die modifizierte nukleotidtriphosphat substrate verwenden können
MXPA99001870A (es) Antagonistas del receptor de taquicinina,no peptidicos.
DE69334243D1 (de) Synthetische polynukleotide
FI913169A0 (fi) Oligonukleotidanaloger med terminala 3'-3'- eller 5'-5'-internukleotidkopplingar.
FR2602776B1 (fr) Diorganopolysiloxane a fonction beta-cetoester utile comme stabilisant des polymeres a base de polychlorure de vinyle
FR2819517B1 (fr) Composition comprenant un nitroxyde, un promoteur et eventuellement un initiateur de radicaux libres
DK1383903T3 (da) Fremgangsmåder til fremstilling af askorbinsyre-intermediater i vært-celler
NO900607L (no) Enzymatisk oppvaskmiddel.
DE69418387T2 (de) Neo-Diol Phosphite als Polymer-Stabilisatoren
IT1284355B1 (it) Scalpello per la perforazione del terreno con gruppo di tenuta del sopporto perfezionato.
ATE110074T1 (de) Quinolyloxazol-2-one, nützlich als proteinkinase- c-inhibitoren.
FI880588A0 (fi) Interpolymerkompositioner och membraner av eten-akrylsyratyp, vilka har foerbaettrad glidbarhet och foerminskad faestfoermaoga.
FR2701335B1 (fr) Bloc de protection différentielle avec sous ensemble fonctionnel testable.
DE69432120T2 (de) Mit chemotherapeutische zusammensetzungenassoziierten genetischen suppressor-elementen
DE69635446D1 (de) Pflanzenpromoter und dessen verwendung zur genexpression
DE59008462D1 (de) Stabilisatordispersionen.
DE60025380D1 (de) Ein-schritttest zum nachweis von antimikrobiellen rückständen in eiern
ATE498014T1 (de) Identifizierung und funktionelle charakterisierung einer ribosomalen s6 proteinkinase
ATE68486T1 (de) 1-((2-fluorophenyl)(4-fluorophenyl)phenylmethyl - 1h-imidazol.
FR2654430B1 (fr) Nouveaux derives de peptides, utilisables comme inhibiteurs des collagenases bacteriennes.